Rare Setback For Merck & Co And AstraZeneca’s Keytruda-Lynparza Combo In Prostate Cancer

All-Comers Approach Disappoints

 
• By Andrew McConaghie
  
Merck 1200
Merck and AstraZeneca's partnership has been successful but metastatic prostate cancer has again proven resistant to combination therapy • Source: Alamy

More from Anticancer

More from Therapy Areas